RaQualia Pharma (TSE:4579) Ending Cash Position: 円0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4579 RaQualia Pharma Inc TSE:4579
58 GF Score
Price 円566.00
GF Value 円748.44
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is RaQualia Pharma Ending Cash Position?

RaQualia Pharma TSE:4579 -1.22% 58 Ending Cash Position is 円0 Mil as of Jun. 2026. GuruFocus rates TSE:4579 with a GF Score™ of 58/100 and a GF Value™ of 円748.44 (Modestly Undervalued). The stock has 3 warning signs investors should review.

RaQualia Pharma's Ending Cash Position for the quarter that ended in Jun. 2026 was 円0 Mil.

RaQualia Pharma's quarterly Ending Cash Position increased from Dec. 2025 (円-299 Mil) to Mar. 2026 (円4,495 Mil) but then declined from Mar. 2026 (円4,495 Mil) to Jun. 2026 (円0 Mil).

RaQualia Pharma's annual Ending Cash Position declined from Dec. 2023 (円3,665 Mil) to Dec. 2024 (円3,142 Mil) but then increased from Dec. 2024 (円3,142 Mil) to Dec. 2025 (円3,244 Mil).

RaQualia Pharma Ending Cash Position Related Terms

RaQualia Pharma Ending Cash Position Historical Data

* Premium members only.

The historical data trend for RaQualia Pharma's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RaQualia Pharma Ending Cash Position Chart

RaQualia Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,240.66 3,679.30 3,664.74 3,141.93 3,244.27

RaQualia Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 858.09 120.72 -298.96 4,494.61 0.00
TSE:4579
58GF Score
RaQualia Pharma Inc TSE:4579
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RaQualia Pharma Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

RaQualia Pharma's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=3141.929+102.345
=3,244

RaQualia Pharma's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0+0
=0

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of 円0 Mil mean?
RaQualia Pharma (TSE:4579) has a Ending Cash Position of 円0 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on RaQualia Pharma and its competitors.
Is RaQualia Pharma's Ending Cash Position too high?
RaQualia Pharma's current Ending Cash Position is 円0 Mil. Overall, RaQualia Pharma has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does RaQualia Pharma's Ending Cash Position compare to VRTX and REGN?
RaQualia Pharma's Ending Cash Position of 円0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on RaQualia Pharma and its competitors. RaQualia Pharma's current Ending Cash Position is 円0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RaQualia Pharma stock overvalued right now?
Based on GuruFocus' analysis, RaQualia Pharma (TSE:4579) is currently considered Modestly Undervalued. The stock's GF Value™ is 円748.44, compared to a current price of 円566.00 — trading 24.4% below its estimated fair value. The current Ending Cash Position is 円0 Mil. RaQualia Pharma's overall GF Score™ is 58/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For RaQualia Pharma (TSE:4579), the current Ending Cash Position is 円0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is RaQualia Pharma (TSE:4579) Overvalued in 2026?

Based on GuruFocus' analysis, RaQualia Pharma stock appears to be undervalued. The current stock price of 円566.00 is trading 24.4% below its estimated GF Value™ of 円748.44. GuruFocus considers RaQualia Pharma to be Modestly Undervalued.

Key valuation signals for TSE:4579:

  • Ending Cash Position: 円0 Mil
  • GF Value™: 円748.44 vs. price of 円566.00 (24.4% below fair value)
  • GF Score™: 58/100 with 3 warning signs

No single metric tells the full story. See the TSE:4579 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

RaQualia Pharma Business Description

Address 1-21-19 Meieki Minami, Nakamura-ku, Nagoya, JPN, 470-2341
RaQualia Pharma Inc operates as a research and development-centered biotechnology company, generating revenue by creating the seeds for novel medicine and licensing them to pharmaceutical companies. The company manages the Sales and licensing of intellectual property for fundamental technologies related to pharmaceutical compounds and candidate compounds for clinical development. Its product portfolio includes, Tegoprazan (K-CAB), Galliprant and Elura both under Veterinary Medicines. The pipeline products include Potassium-Competitive Acid Blocker, Ghrelin Receptor Agonist, TRPM8 Blocker and 5-HT4 Agonist studied under different phases of development.
58GF Score

Get the complete analysis for TSE:4579

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円566.00
Price
円748.44
GF Value